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ABSTRACT
Objectives: Persistence of human papillomaviruses
(HPVs) is necessary for cervical carcinogenesis. We
evaluated incidence and duration of type-specific HPV
infections and the influence of age and number of
sexual partners.
Methods: Data were obtained from 553 women
(15–25 years), who were seronegative and
DNA-negative for high-risk HPV (HR-HPV) types and
were enrolled in the placebo arm of a randomised trial
of the HPV-16/18 vaccine (NCT00689741/
NCT00120848). They were followed for 6.3 years.
Cervicovaginal samples were self-collected at 3-month
intervals for up to 27 months, and cervical samples
were collected by clinicians at 6-month intervals until
study end. Samples were tested for HPV types using
a broad-spectrum PCR assay. Incidence rate ratios
(RRs) and 95% CIs were used to estimate the
association among age, sexual habits and HPV
acquisition.
Results: Incidence rates (95% CI) using cervical
samples were 11.8 (10.4 to 13.4) and 5.6 (4.7 to 6.6)
per 1000 women-months for HR-HPVs and low-risk
HPVs (LR-HPVs), respectively. Equivalent rates in
combined cervicovaginal and cervical samples were
17.2 (15.4 to 19.2) and 6.9 (5.9 to 8.0), respectively.
54 per cent of HR-HPV types from combined
cervicovaginal and cervical samples persisted for
1 year compared with 32.3% for LR-HPV types. The
risk of acquiring any HPV infection was higher among
women aged <21 years (RR=1.33, 95% CI 1.1 to 1.7)
and women having >1 sexual partner (RR=1.83, 95%
CI 1.4 to 2.4) at baseline.
Conclusions: HR-HPV infections were more common
and lasted longer on average than LR-HPV infections.
HPV acquisition was more common in younger women
with multiple sexual partners.
Trial registration number: NCT00689741,
NCT00120848; Post-results.
INTRODUCTION
Human papillomavirus (HPV) is the cause of
cervical cancer.1 2 HPV infection is usually
asymptomatic and generally clears within
2 years for most infected individuals; yet a
small proportion of infections persist and
progress towards cervical cancer.3–7 The risk
of cervical neoplasia is greatest among
women with persistent high-risk HPV
(HR-HPV) infections, which normally persist
longer than those associated with low-risk
HPV (LR-HPV) types.6–10 Understanding the
natural history of HPV infection and its pro-
gression to cervical neoplasia is essential in
planning successful cervical cancer control
programmes.11 12 Determinants of HPV
Strengths and limitations of this study
▪ This study looks into the epidemiology of human
papillomavirus (HPV) by assessing the impact
and duration of specific HPV-type infections and
by taking into account the age and the number
of sexual partners.
▪ Improved understanding of type-specific HPV
incidence and persistence may assist in design-
ing cervical cancer screening algorithms based
on molecular testing for high-risk HPVs.
▪ We analysed data from women aged 15–25 years
who participated as control within a randomised
clinical trial looking at the efficacy of the HPV-16/
18 AS04-adjuvanted vaccine.
▪ The envisioned study limitation is the duration of
self-collected samples over 2 years, which is
counterbalanced by the duration of other
samples collected by clinicians (over 6 years).
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infection, transmission and development of cervical
cancer include sexual habits, use of oral contraceptives,
multiparity and smoking.13 14
Currently, little is known about the duration of infec-
tions with different HPV types.2 3 5 15 16 Previous studies
conducted on the natural history of HPV have mostly
focused on broader groups of HPV types, have considered
prevalence rather than incidence of infections or have
been limited to cohort data with short follow-up.16–23
In the current study, we retrospectively analysed
cohort data from participants enrolled in the placebo
arm of a randomised controlled trial assessing the effi-
cacy of the HPV-16/18 AS04-adjuvanted vaccine (Cervarix,
GSK Vaccines) in young healthy women (NCT00689741).
Clinician-collected cervical and self-collected cervicovagi-
nal samples were obtained and used complementarily to
study persistence and clearance of HPV infections. This
trial recruited prescreened women not showing any sero-
logical or virological evidence of HR-HPV infections.
This permitted assessing the type-specific incidence and
duration of HPV infections among women presumably
without prior exposure to infections with specific
HR-HPVs.
METHODS
Study design and participants
A phase II, double-blind, randomised controlled trial of
HPV-16/18 AS04-adjuvanted vaccine was conducted
among 1113 young women aged 15–25 years. Detailed
information on the design and follow-up procedures has
been presented elsewhere.24 25 Briefly, following an initial
phase of recruitment between July 2000 and September
2001, participants who were followed up until 18 months
were asked to participate in an extended follow-up period
until 27 months after receiving the first vaccine dose
(HPV-001 (NCT00689741, Clinicaltrials.gov)). On com-
pletion of this phase, vaccine and placebo recipients were
invited to participate in a long-term follow-up study of
∼3-year duration (up to 76 months) (HPV-007
(NCT00120848, Clinicaltrials.gov)).25 26 Online supple-
mentary figure 1 depicts the successive phases of the
study.
The current analysis was restricted to a cohort of 553
individuals randomised to the placebo arm of this trial
(received only aluminium hydroxide adjuvant). Women
who were seronegative for HPV16 and HPV18 antibodies
and HPV DNA-negative for 14 HR-HPV types (16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) at
screening visit had no more than six sexual partners and
had no prior abnormal Pap smear or treatment for cer-
vical disease were enrolled in this study. Women who
participated in the initial phase and received three
doses of placebo were eligible to participate in the
extended and long-term follow-up phases.26
The study protocol and written informed consent,
obtained at the screening visit from all participants or
from a legally acceptable representative for those
younger than the legal age of consent, were approved by
independent ethics committees or institutional review
boards of the respective study centres (see online sup-
plementary table S1).
Specimen collection and HPV DNA testing
Cervical samples were collected for cytology and HPV
DNA testing at the screening visit; at months 6, 12 and
18 in the initial phase and every 6 months in the long-
term follow-up period (after vaccination). Self-collected
cervicovaginal samples were obtained at months 0, 6 and
then every 3 months until the end of the extended
follow-up phase (see online supplementary figure 1).
Colposcopy and histology were carried out according to
a standardised protocol.24–26 DNA was isolated from the
specimens and was tested for 25 HPV genotypes (6, 11,
16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53,
54, 56, 58, 59, 66, 68, 70 and 74) using the broad-
spectrum PCR SPF10 LiPA25 system
24 and by type-specific
PCR for HPV types 16 and 18. HPV types 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 were classified as
HR-HPV types and the remainder as LR-HPV types.
HPV types were also grouped according to
Alphapapillomavirus species 6, 7, 8, 9 and 10 of the genus
Alphapapillomavirus.
Statistical analysis
Analyses were performed for type-specific and/or
grouped HPV infections (ie, LR-HPV, HR-HPV, any HPV
or HPV α species). Combined clinician-collected cervical
and self-collected cervicovaginal samples were used in
all statistical analyses unless otherwise specified. We used
several analytic approaches to study the natural history
of cervical HPV infection.
The incidence rate for a given HPV genotype was cal-
culated for women at risk for that type even if they were
positive for other types. The cumulative probability of
acquiring grouped HPV infection (eg, HR-HPV, LR-HPV
or by α species) over the entire study period was esti-
mated using the Kaplan-Meier (K-M) method. For clear-
ance estimates, two different definitions were used. In
the liberal (less stringent) definition, time to clearance
for a given type was defined as the time elapsed between
initial positivity and the visit when a participant was no
longer positive for that type. In the conservative defin-
ition (stringent), we considered clearance to have
occurred only after two consecutively negative visits had
elapsed. The K-M method was also used to estimate the
proportion of women who remained positive for
grouped HPV infections by considering their first infec-
tion as the index infection since time 0. In the case of
multiple and coinfections within the HR groups or LR
groups, their longest persisting infection must have been
cleared in order to assign clearance status. Infections
were only considered to be cleared when a women was
no longer positive for any HR-HPV or LR-HPV types.
Incidence rate ratios (RRs) and 95% CIs were com-
puted to estimate the association among age (<21, 21+
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years), number of sexual partners (0/1, 2+) and the risk
of HPV acquisition. K-M graphs and log-rank tests, used
to identify differences in HPV acquisition and clearance
in women, were stratified by age and number of sexual
partners.
RESULTS
At the time of this analysis, there were 6618 samples
with HPV DNA typing, with an average of 9 visits per
woman. The mean and median follow-up durations were
51.8 and 68.2 months, respectively. Online supplemen-
tary figure 2 shows for each study visit, the distribution
of the actual time elapsed since screening, with the
majority of participants returning on time for scheduled
follow-up visits. Approximately 60% of participants
returned for the follow-up beyond 6 years (see online
supplementary figure 2). Online supplementary table S2
shows the sociodemographic characteristics and smoking
and reproductive health history for the 553 women
included in the cohort. Slightly more than half of the
sample was enrolled in American and Canadian centres
and the remainder in multiple centres in Brazil. Most
women were single or divorced and attained more than
high school education. More than 70% of the women
had at most one lifetime sexual partner.
Incidence of HPV infection
During follow-up, any HPV infection was detected in
320/553 (57.9%) initially enrolled women; 201/553
(36.3%) were infected with multiple types at the same
visit, regardless of the sampling method.
Table 1 Incidence of infections with individual and grouped HPV types according to the type of cell sampling
Combined cervical and cervicovaginal samples Cervical samples only
HPV type,
species
Women-months
of follow-up
Incident
cases
Incident rate per
1000 women-months
(95% CI)
Women-months
of follow-up
Incident
cases
Incident rate per
1000 women-months
(95% CI)
HPV6 27 928 53 1.90 (1.45 to 2.48) 28 033 40 1.43 (1.05 to 1.95)
HPV11 28 971 26 0.90 (0.61 to 1.32) 29 002 16 0.55 (0.34 to 0.90)
HPV16 25 976 108 4.16 (3.44 to 5.02) 26 723 84 3.14 (2.54 to 3.89)
HPV18 27 264 72 2.64 (2.10 to 3.33) 27 843 52 1.87 (1.42 to 2.45)
HPV31 27 874 56 2.01 (1.55 to 2.61) 28 140 41 1.46 (1.07 to 1.98)
HPV33 28 600 31 1.08 (0.76 to 1.54) 28 602 21 0.73 (0.48 to 1.13)
HPV34 29 443 8 0.27 (0.14 to 0.54) 29 231 4 0.14 (0.05 to 0.36)
HPV35 28 992 23 0.79 (0.53 to 1.19) 28 762 19 0.66 (0.42 to 1.04)
HPV39 27 840 62 2.23 (1.74 to 2.86) 27 933 48 1.72 (1.29 to 2.28)
HPV40 28 909 25 0.86 (0.58 to 1.28) 29 068 13 0.45 (0.26 to 0.77)
HPV42 29 313 13 0.44 (0.26 to 0.76) 29 210 6 0.21 (0.09 to 0.46)
HPV43 28 989 21 0.72 (0.47 to 1.11) 29 068 11 0.38 (0.21 to 0.68)
HPV44 29 058 24 0.83 (0.55 to 1.23) 28 864 19 0.66 (0.42 to 1.03)
HPV45 28 867 33 1.14 (0.81 to 1.61) 28 595 29 1.01 (0.70 to 1.46)
HPV51 26 348 98 3.72 (3.05 to 4.53) 27 339 72 2.63 (2.09 to 3.32)
HPV52 26 233 91 3.47 (2.82 to 4.26) 27 076 68 2.51 (1.98 to 3.19)
HPV53 26 485 85 3.21 (2.59 to 3.97) 26 952 69 2.56 (2.02 to 3.24)
HPV54 28 146 42 1.49 (1.10 to 2.02) 28 447 31 1.09 (0.77 to 1.55)
HPV56 27 879 58 2.08 (1.61 to 2.69) 28 289 42 1.48 (1.10 to 2.01)
HPV58 28 614 34 1.19 (0.85 to 1.66) 28 591 26 0.91 (0.62 to 1.34)
HPV59 28 809 26 0.90 (0.61 to 1.33) 28 925 16 0.55 (0.34 to 0.90)
HPV66 27 222 69 2.53 (2.00 to 3.21) 27 579 54 1.96 (1.50 to 2.56)
HPV68 27 832 53 1.90 (1.45 to 2.49) 28 241 41 1.45 (1.07 to 1.97)
HPV70 29 061 22 0.76 (0.50 to 1.15) 28 970 17 0.59 (0.36 to 0.94)
HPV74 28 657 34 1.19 (0.85 to 1.66) 28 853 24 0.83 (0.56 to 1.24)
Any HPV 15 530 320 20.61 (18.47 to 22.99) 18 859 265 14.05 (12.46 to 15.85)
HR-HPV 17 518 301 17.18 (15.35 to 19.24) 20 806 246 11.82 (10.43 to 13.40)
LR-HPV 23 550 162 6.88 (5.90 to 8.02) 24 686 137 5.55 (4.69 to 6.56)
Species-6 23 277 164 7.05 (6.05 to 8.21) 24 791 132 5.32 (4.49 to 6.31)
Species-7 23 123 173 7.48 (6.45 to 8.68) 24 906 138 5.54 (4.69 to 6.55)
Species-8 28 300 40 1.41 (1.04-1.93) 28 768 23 0.80 (0.53 to 1.20)
Species-9 21 424 212 9.90 (8.65 to 11.32) 23 718 163 6.87 (5.89 to 8.01)
Species-10 26 661 91 3.41 (2.78 to 4.19) 27 371 67 2.45 (1.93 to 3.11)
α species 6=HPVs 53, 56, 66; α species 7=HPVs 18, 39, 45, 59, 68, 70; α species 8=HPVs 40, 43; α species 9=HPVs 16, 31, 33, 35, 52, 58;
α species 10=HPVs 6, 11, 44.
HPV, human papillomavirus; HR-HPV, high-risk HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68); LR-HPV, low-risk HPV (6, 11,
34, 40, 42, 43, 44, 53, 54, 59, 70 and 74).
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Table 2 Median and mean durations of infection in months and proportion of persistent infection for individual and grouped HPV types (combined cervical and
cervicovaginal samples)
Liberal definition: clearance defined as first negative results
postinfection
Conservative definition: clearance defined as two consecutive negative
results postinfection
HPV type,
species
No. of
events
Median duration of
infection (95% CI)
Mean duration of
infection (95% CI)
% of persistent
infection
(1-year)
No. of
events
Median duration of
infection (95% CI)
Mean duration of
infection (95% CI)
% of persistent
infection
(1-year)
HPV6 43 6.5 (5.7 to 9.0) 9.5 (7.5 to 11.5) 16.1 41 7.2 (5.7 to 9.6) 10.0 (7.9 to 12.2) 18.2
HPV11 24 7.2 (5.8 to 11.7) 9.2 (6.9 to 11.4) 25.5 23 9.8 (6.0 to 12.6) 11.0 (7.9 to 14.1) 32.3
HPV16 82 11.8 (10.3 to 16.7) 15.8 (13.0 to 18.5) 49.0 69 16.9 (11.7 to 22.6) 21.3 (17.3 to 25.2) 60.6
HPV18 61 6.2 (5.8 to 11.1) 10.8 (8.3 to 13.3) 33.0 57 7.7 (5.9 to 12.2) 12.1 (9.4 to 14.9) 39.3
HPV31 44 7.4 (5.9 to 12.1) 10.9 (8.4 to 13.4) 36.6 39 10.6 (6.7 to 16.7) 14.0 (10.8 to 17.1) 46.7
HPV33 27 8.0 (6.2 to 10.6) 10.0 (7.3 to 12.7) 27.1 24 8.7 (6.2 to 13.3) 11.3 (8.3 to 14.3) 40.2
HPV34 8 6.0 (2.5 to 11.5) 8.0 (5.1 to 10.8) 12.5 8 6.0 (2.5 to 11.5) 8.0 (5.1 to 10.8) 12.5
HPV35 21 12.1 (6.2 to 16.6) 14.8 (10.7 to 18.8) 50.3 16 14.3 (11.3 to 24.6) 17.6 (12.7 to 22.5) 59.0
HPV39 49 6.5 (6.0 to 8.3) 11.0 (8.5 to 13.5) 30.2 44 8.1 (6.5 to 14.1) 13.8 (10.7 to 16.9) 40.4
HPV40 23 6.0 (4.4 to 8.1) 7.2 (5.5 to 8.9) 13.5 21 6.0 (4.4 to 9.5) 7.7 (5.8 to 9.7) 17.4
HPV42 11 6.0 (3.2 to 10.0) 6.8 (5.2 to 8.3) 0.0 9 7.2 (3.2 to 34.8) 13.0 (5.2 to 20.8) 22.9
HPV43 20 5.9 (4.4 to 8.5) 7.9 (5.5 to 10.4) 17.1 15 6.0 (4.4 to 16.6) 10.0 (6.8 to 13.2) 31.0
HPV44 21 6.9 (4.4 to 13.9) 11.2 (7.0 to 15.4) 32.6 18 7.0 (6.0 to 19.3) 14.4 (9.1 to 19.8) 39.4
HPV45 28 7.0 (5.5 to 9.2) 8.9 (6.8 to 11.0) 21.8 25 7.2 (5.6 to 11.6) 9.8 (7.3 to 12.2) 24.9
HPV51 82 7.4 (6.0 to 10.6) 11.3 (9.1 to 13.5) 33.6 69 10.3 (6.9 to 12.5) 15.4 (11.7 to 19.1) 40.8
HPV52 76 10.7 (7.2 to 14.5) 14.9 (12.3 to 17.5) 45.3 64 16.8 (10.8 to 21.4) 19.9 (16.2 to 23.6) 60.3
HPV53 81 11.2 (9.3 to 12.0) 12.0 (10.3 to 13.6) 40.8 70 12.1 (11.1 to 14.7) 15.5 (12.9 to 18.0) 50.1
HPV54 38 6.0 (5.3 to 7.6) 8.6 (6.8 to 10.4) 29.5 32 6.9 (5.8 to 12.5) 10.2 (8.0 to 12.4) 39.4
HPV56 46 6.1 (5.3 to 12.1) 11.9 (8.8 to 15.0) 36.5 39 12.1 (6.0 to 18.3) 14.7 (11.0 to 18.5) 52.9
HPV58 26 9.7 (5.3 to 12.0) 11.5 (8.4 to 14.6) 30.8 24 11.4 (7.5 to 21.8) 13.7 (10.4 to 17.0) 44.8
HPV59 25 7.0 (5.3 to 11.6) 8.5 (6.5 to 10.5) 28.1 22 7.3 (5.3 to 13.4) 9.0 (6.8 to 11.2) 34.4
HPV66 59 6.5 (5.8 to 9.3) 9.4 (7.7 to 11.0) 25.4 50 9.0 (6.0 to 11.6) 12.4 (9.6 to 15.2) 36.7
HPV68 45 6.2 (5.8 to 12.3) 10.7 (8.4 to 13.1) 36.6 42 7.8 (6.0 to 14.0) 12.7 (10.1 to 15.3) 45.1
HPV70 18 10.2 (5.5 to 18.9) 18.0 (9.9 to 26.0) 42.5 14 12.5 (6.0 to 25.8) 22.5 (12.8 to 32.2) 53.1
HPV74 24 6.5 (5.3 to 18.7) 12.2 (8.8 to 15.6) 42.0 22 11.0 (5.3 to 18.7) 14.1 (9.9 to 18.3) 48.6
Any HPV 251 14.5 (11.8 to 16.8) 21.9 (19.4 to 24.3) 53.7 210 25.0 (18.0 to 27.9) 29.7 (26.7 to 32.7) 66.4
HR-HPV 232 13.7 (10.6 to 16.8) 19.5 (17.3 to 21.8) 54.1 187 24.6 (20.1 to 28.8) 28.1 (25.0 to 31.2) 67.4
LR-HPV 150 8.6 (6.5 to 10.9) 11.6 (10.1 to 13.1) 32.3 130 11.6 (10.2 to 12.5) 14.8 (12.8 to 16.8) 44.3
Species-6 146 9.9 (7.5 to 11.6) 12.1 (10.6 to 13.7) 39.3 122 11.7 (9.7 to 13.0) 16.5 (14.0 to 19.0) 48.9
Species-7 148 7.3 (6.2 to 11.3) 12.6 (10.7 to 14.4) 38.9 133 11.7 (7.3 to 14.1) 16.4 (14.0 to 18.7) 49.4
Species-8 40 5.9 (5.0 to 6.2) 7.4 (5.8 to 9.0) 15.0. 32 6.0 (5.5. to 9.5) 8.8 (6.7 to 11.0) 24.1
Species-9 167 13.1 (10.6 to 16.7) 16.7 (14.7 to 18.8) 52.1 136 20.0 (15.9 to 23.3) 23.9 (20.7 to 27.1) 65.1
Species-10 79 7.0 (6.0 to 8.8) 10.0 (8.3 to 11.7) 29.0 72 8.7 (6.2 to 11.7) 11.9 (9.8 to 14.0) 35.8
α species 6=HPVs 53, 56, 66; α species 7=HPVs 18, 39, 45, 59, 68, 70; α species 8=HPVs 40, 43; α species 9=HPVs 16, 31, 33, 35, 52, 58; α species 10=HPVs 6, 11, 44.
HPV, human papillomavirus; HR-HPV, high-risk HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68); LR-HPV, low-risk HPV (6, 11, 34, 40, 42, 43, 44, 53, 54, 59, 70 and 74).
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Table 3 Incidence rate of infection with individual and grouped HPV types using combined cervical and cervicovaginal samples, according to age and number of sexual
partners
Age Number of sexual partners
21+ years <21 years 0/1 2+
HPV type
IR per 1000
women-months (95% CI)
IR per 1000
women-months (95% CI) RR (95% CI)
IR per 1000
women-months (95% CI)
IR per 1000
women-months (95% CI) RR (95% CI)
HPV6 1.14 (0.69 to 1.89) 2.59 (1.89 to 3.56) 2.26 (1.22 to 4.44) 1.47 (0.90 to 2.41) 2.16 (1.48 to 3.15) 1.46 (0.76 to 2.91)
HPV11 0.60 (0.30 to 1.2) 1.16 (0.73 to 1.84) 1.93 (0.80 to 5.14) 0.53 (0.24 to 1.19) 0.99 (0.58 to 1.71) 1.86 (0.66 to 5.97)
HPV16 2.49 (1.75 to 3.55) 5.64 (4.51 to 7.07) 2.26 (1.47 to 3.56) 3.22 (2.29 to 4.54) 4.98 (3.84 to 6.45) 1.54 (0.99 to 2.45)
HPV18 2.05 (1.40 to 3.01) 3.18 (2.38 to 4.25) 1.55 (0.94 to 2.62) 1.57 (0.97 to 2.52) 3.30 (2.42 to 4.50) 2.11 (1.17 to 3.96)
HPV31 1.47 (0.94 to 2.30) 2.50 (1.81 to 3.45) 1.71 (0.96 to 3.14) 0.80 (0.42 to 1.55) 2.78 (1.99 to 3.89) 3.46 (1.62 to 8.20)
HPV33 0.91 (0.52 to 1.60) 1.17 (0.74 to 1.86) 1.29 (0.59 to 2.93) 0.81 (0.42 to 1.56) 1.57 (1.01 to 2.44) 1.93 (0.84 to 4.82)
HPV34 0.15 (0.04 to 0.59) 0.38 (0.17 to 0.85) 2.57 (0.46 to 26.0) 0.27 (0.09 to 0.82) 0.30 (0.11 to 0.80) 1.13 (0.19 to 7.71)
HPV35 0.75 (0.41 to 1.40) 0.83 (0.48 to 1.44) 1.11 (0.45 to 2.82) 0.72 (0.36 to 1.44) 0.84 (0.46 to 1.51) 1.16 (0.42 to 3.32)
HPV39 1.94 (1.31 to 2.88) 2.49 (1.81 to 3.44) 1.28 (0.75 to 2.22) 2.26 (1.51 to 3.37) 2.40 (1.68 to 3.44) 1.06 (0.60 to 1.90)
HPV40 0.83 (0.46 to 1.49) 0.91 (0.54 to 1.53) 1.10 (0.46 to 2.67) 0.91 (0.49 to 1.68) 1.00 (0.58 to 1.71) 1.10 (0.45 to 2.80)
HPV42 0.45 (0.20 to 1.00) 0.44 (0.21 to 0.93) 0.98 (0.28 to 3.53) 0.09 (0.01 to 0.63) 0.84 (0.46 to 1.51) 9.48 (1.38 to 408.0)
HPV43 0.45 (0.20 to 1.00) 0.97 (0.58 to 1.61) 2.17 (0.79 to 6.81) 0.91 (0.49 to 1.68) 0.60 (0.30 to 1.21) 0.67 (0.23 to 1.88)
HPV44 0.38 (0.16 to 0.90) 1.21 (0.77 to 1.90) 3.23 (1.17 to 11.06) 0.71 (0.36 to 1.43) 0.68 (0.36 to 1.32) 0.96 (0.37 to 2.85)
HPV45 0.83 (0.46 to 1.50) 1.42 (0.94 to 2.16) 1.71 (0.80 to 3.91) 0.99 (0.55 to 1.79) 1.46 (0.93 to 2.29) 1.48 (0.67 to 3.44)
HPV51 2.66 (1.89 to 3.74) 4.53 (3.54 to 5.80) 1.71 (1.10 to 2.68) 3.09 (2.18 to 4.36) 4.59 (3.50 to 6.00) 1.49 (0.94 to 2.38)
HPV52 2.22 (1.53 to 3.21) 4.58 (3.57 to 5.87) 2.07 (1.30 to 3.35) 2.90 (2.03 to 4.15) 3.85 (2.87 to 5.15) 1.33 (0.82 to 2.18)
HPV53 2.52 (1.78 to 3.59) 3.84 (2.94 to 5.01) 1.52 (0.96 to 2.44) 2.59 (1.78 to 3.78) 3.71 (2.75 to 5.00) 1.43 (0.86 to 2.41)
HPV54 0.91 (0.52 to 1.61) 1.94 (1.35 to 2.80) 2.13 (1.05 to 4.59) 1.38 (0.83 to 2.29) 1.67 (1.09 to 2.56) 1.21 (0.60 to 2.53)
HPV56 1.47 (0.93 to 2.30) 2.57 (1.87 to 3.53) 1.75 (0.99 to 3.22) 1.75 (1.11 to 2.74) 1.82 (1.21 to 2.75) 1.05 (0.54 to 2.03)
HPV58 0.98 (0.57 to 1.69) 1.38 (0.90 to 2.11) 1.40 (0.67 to 3.05) 0.91 (0.49 to 1.68) 1.23 (0.75 to 2.00) 1.35 (0.58 to 3.33)
HPV59 0.76 (0.41 to 1.40) 1.04 (0.63 to 1.69) 1.37 (0.59 to 3.38) 0.35 (0.13 to 0.94) 1.25 (0.76 to 2.04) 3.53 (1.14 to 14.52)
HPV66 1.48 (0.95 to 2.32) 3.43 (2.59 to 4.53) 2.31 (1.34 to 4.16) 2.70 (1.86 to 3.91) 2.62 (1.85 to 3.70) 0.97 (0.57 to 1.67)
HPV68 1.65 (1.07 to 2.53) 2.14 (1.51 to 3.02) 1.30 (0.73 to 2.37) 1.46 (0.90 to 2.39) 2.53 (1.78 to 3.60) 1.73 (0.92 to 3.39)
HPV70 0.68 (0.36 to 1.31) 0.83 (0.48 to 1.42) 1.21 (0.48 to 3.20) 0.62 (0.30 to 1.30) 0.84 (0.47 to 1.52) 1.35 (0.48 to 4.12)
HPV74 0.90 (0.51 to 1.58) 1.45 (0.95 to 2.20) 1.61 (0.76 to 3.58) 1.07 (0.61 to 1.89) 1.40 (0.88 to 2.22) 1.30 (0.59 to 2.97)
Any HPV 17.58 (14.88 to 20.78) 23.48 (20.29 to 27.18) 1.33 (1.06 to 1.68) 15.63 (12.90 to 18.95) 28.66 (24.62 to 33.35) 1.83 (1.43 to 2.36)
HR-HPV 13.80 (11.58 to 16.45) 20.60 (17.76 to 23.90) 1.49 (1.18 to 1.89) 13.34 (10.93 to 16.27) 22.88 (19.60 to 26.72) 1.72 (1.33 to 2.23)
LR-HPV 5.94 (4.66 to 7.57) 7.78 (6.37 to 9.49) 1.31 (0.95 to 1.82) 6.37 (4.94 to 8.23) 7.46 (5.96 to 9.34) 1.17 (0.82 to 1.67)
Species-6 5.09 (3.93 to 6.60) 8.76 (7.23 to 10.60) 1.72 (1.23 to 2.42) 5.79 (4.44 to 7.56) 8.27 (6.66 to 10.27) 1.43 (1.00 to 2.05)
Species-7 6.88 (5.49 to 8.63) 8.10 (6.65 to 9.88) 1.18 (0.86 to 1.61) 5.10 (3.86 to 6.75) 9.92 (8.13 to 12.12) 1.94 (1.37 to 2.80)
Species-8 1.06 (0.63 to 1.79) 1.73 (1.18 to 1.73) 1.63 (0.82 to 3.38) 1.68 (1.06 to 2.66) 1.32 (0.82 to 2.11) 0.78 (0.38 to 1.61)
Species-9 7.23 (5.79 to 9.03) 12.42 (10.47 to 14.73) 1.72 (1.29 to 2.30) 7.44 (5.84 to 9.49) 12.23 (10.15 to 14.73) 1.64 (1.20 to 2.27)
Species-10 1.98 (1.34 to 2.93) 4.75 (3.73 to 6.04) 2.40 (1.49 to 3.97) 2.47 (1.68 to 3.63) 3.81 (2.84 to 5.10) 1.54 (0.93 to 2.60)
α species 6=HPVs 53, 56, 66; α species 7=HPVs 18, 39, 45, 59, 68, 70; α species 8=HPVs 40, 43; α species 9=HPVs 16, 31, 33, 35, 52, 58; α species 10=HPVs 6, 11, 44.
HPV, human papillomavirus; HR-HPV, high-risk HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68); IR, incidence rate; LR-HPV, low-risk HPV (6, 11, 34, 40, 42, 43, 44, 53, 54, 59,
70 and 74); RR, rate ratio.
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Table 1 shows the incidence rates of type-specific and
grouped HPV infections in combined cervical and self-
collected cervicovaginal samples as well as in cervical
samples. Kappa statistics showed an 85% agreement
between self-collected and clinician-collected samples
(results not shown). On the basis of analyses of the com-
bined cervical and cervicovaginal samples, the five most
common HPV types (incidence rate per 1000 women-
months; 95% CI) were HPV16 (4.2; 3.4 to 5.0), HPV51
(3.7; 3.1 to 4.5), HPV52 (3.5; 2.8 to 4.3), HPV53 (3.2;
2.6 to 4.0) and HPV18 (2.6; 2.1 to 3.3) (table 1). Using
cervical samples only, the incidence rates were slightly
lower and the most common types were similar with
exception of HPV18 (table 1). The incidence rates (95%
CI) for any HR-HPV type and any LR-HPV type using
combined cervical and cervicovaginal samples were 17.2
(15.4 to 19.2) and 6.9 (5.9 to 8.0), respectively. The cor-
responding values in cervical samples were 11.8 (10.4 to
13.4) and 5.6 (4.7 to 6.6), respectively (table 1). The
cumulative rates of any HPV infection were 28.7%
(1-year) and 49.7% (2 years) using either sampling tech-
nique (data not shown).
Clearance of HPV infection
The pattern of HPV clearance based on the two differ-
ent definitions is shown in table 2. Using the liberal def-
inition for combined cervical and cervicovaginal
samples, more than half of the HR-HPVs (54.1%) and
nearly one-third of LR-HPVs (32.3%) persisted for
longer than 1 year. The median time (months; 95% CI)
to clear an infection tended to be longer for most
HR-HPV types, for example, HPV16 (11.8; 10.3 to 16.7),
HPV35 (12.1; 6.2 to 16.6), HPV52 (10.7; 7.2 to 14.5)
compared to LR-HPV types, for example, HPV6 (6.5; 5.7
to 9.0), HPV11 (7.2; 5.8 to 11.7). The mean duration of
infections was longer than the median durations and was
between 7 and 22 months depending on the risk-based
grouping (HR-HPV or LR-HPV). Further, when analyses
were restricted to long-term follow-up (40–76 months),
the median durations were 10.5 and 5.6 months for
HR-HPV and LR-HPV types, respectively. On the other
hand, when restricted to the 0–18 months’ follow-up
period and cervical samples, the corresponding median
durations were 13.1 and 11.7 months, respectively.
As expected, the stringent definition of clearance
yielded longer estimates of mean and median durations
than the liberal definition, that is, 29.7 (95% CI 26.7 to
32.7) and 25.0 (95% CI 18.0 to 27.9) months versus 21.9
(19.4 to 24.3) and 14.5 (11.8 to 16.8) months, respect-
ively, for estimates associated with any HPV type (table 2).
Further, in our cohort, 30% of LR-HPV and 49% of
HR-HPV samples were accompanied by other HPV
types at the same visit. Using liberal definition, women
with multiple infections generally took a longer time to
Figure 1 Cumulative probability of persistent detection of the first episode of HPV infection (as per liberal definition) over
time stratified by age (upper graphs A, B, C; solid line <21 years and dashed line ≥21 years) and sexual partners (lower
graphs D, E, F; solid line ≥2 partners, dashed line 0/1 partner). Log-rank test p values; A=0.0806, B=0.1276, C=0.9338,
D=0.3436, E=0.4601, F=0.2186. (A and D) Any HPV type; (B, E) HR-HPV; and (C and F) LR-HPV. The Y-axis represents
the probability that HPV infections remain detectable. Clearance of an infection episode as per the liberal definition (see
text for details); combined cervical and cervicovaginal samples. HPV, human papillomavirus; HR-HPV, high-risk HPV;
LR-HPV, low-risk HPV.
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clear their infections (median=20.6 months) compared
to those with a single infection of any type
(median=10.5 months).
Age and number of sexual partners as risk factors
Table 3 presents incidence RR according to age and
number of sexual partners. Higher type-specific and
grouped incidence (RRs>1) was the rule among younger
women (<21 years) and among women with multiple
sexual partners (≥2 partners). The risk of acquiring any
type of HPV infection was 1.33 times (95% CI 1.1 to 1.7)
higher in women aged <21 years compared with women
aged ≥21 years. Likewise, women with more than one
sexual partner were at 1.83 times (95% CI 1.4 to 2.4)
higher risk than those with no/single partner. While
younger women (<21 years) had an increased risk of
infection with HPV α species 6, 9 and 10, those with
multiple sexual partners had marginally increased risks
of infection with HPV α species groups 7, 9 and 10.
The cumulative probability of clearance of HPV infec-
tions, according to the liberal definition and stratified by
age and multiple sexual partners, is shown in figure 1.
Younger women and women with multiple sexual part-
ners took slightly longer to clear the infections, but dif-
ferences were not significant based on log-rank tests.
Furthermore, the cumulative probability of detecting an
HPV infection was significantly higher in younger
women and women with multiple sexual partners, as
depicted in figure 2.
DISCUSSION
We studied the early natural history of true incident
genital HPV infections in a cohort characterised by ser-
ology and cervical sampling, in addition to a restriction in
maximum number of sexual partners, which permitted
ascertaining that participants had minimal previous expos-
ure to HPV. Our results showed HR-HPV infections to be
more common and of longer duration than LR-HPV
infections. The study also revealed that younger women
with multiple sex partners were at a higher risk of acquir-
ing HPV infections than those with no/single sex partner.
Incidence rates of type-specific HPV infections were
compared according to different sampling strategies: (1)
clinician-collected cervical and (2) clinician plus self-
collected cervicovaginal sampling. The agreement
between self-collected and clinician-collected samples
for the detection of HPV DNA was reasonably good in
this study population, that is, 85% of positive tests were
observed when both samples were available, that is, 6, 12
and 18 months. The incidence rate we observed for
Figure 2 Cumulative probability of detecting an HPV infection over time stratified by the age group (upper graphs A, B, C; solid
line <21 years and dashed line ≥21 years) and number of sexual partners (lower graphs D, E, F; solid line ≥2 partners and
dashed line 0/1 partner). Log-rank test p values; A=0.0099, B<0.0001, C=0.122, D<0.0001, E=0.0007, F=0.2712. (A and D) Any
HPV type; (B and E), HR-HPV; and (C and F) LR-HPV. The Y-axis represents cumulative proportion of infections detected.
Combined cervical and cervicovaginal samples. HPV, human papillomavirus; HR-HPV, high-risk HPV; LR-HPV, low-risk HPV.
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HR-HPV infections was essentially the same as that seen
in a population of Dutch women of comparable age,27
although the latter study observed a higher rate (14.3/
1000 women-months, 95% CI 12.8 to 15.9) of LR-HPVs
than we did in the present study (6.9 per 1000
women-months).
Approximately 58% of enrolled women were infected
with HPV at some time during the follow-up. This is in
agreement with previous studies, where 36-month cumu-
lative rates ranged from 43% to 60% among university
students.16 18 28 Cumulative rates of HPV16, HPV18 or
other types of α-7/9 species were also comparable with
the rates reported in other studies.15 16 18 Further, 30%
of LR-HPVs and 49% of HR-HPVs samples were accom-
panied by other HPV types at the same visit.
Defining clearance of incident infections in the
current study using the more conservative stringent def-
inition more likely reflects the truly resolved infections
and not false-negative results due to poor sampling, low
levels of viral DNA or other measurement errors.18 29–31
Therefore, duration of infections was clearly longer
when using this definition. Similarly, other studies have
also shown differences in duration using various
definitions.32 33
Relative to other studies, we have seen similar rates of
persistent infections in our cohort. On the basis of the
liberal definition, the median duration until clearance
of any HPV infection was 14.5 months, which is compar-
able to the median duration observed in a previous
study (17.3 months).18
Differences in time intervals between samplings may
explain the differences in perceived duration of an
infection episode. The shorter intervals between cervi-
covaginal sampling (3 months) provide a more detailed
assessment of the fluctuation in HPV detection over
time relative to what can be observed with cervical sam-
pling, which was performed at regular intervals of
6 months across the initial phase and the long-term
follow-up period. Conceivably, interval fluctuation in
HPV detection would not have affected clinical defini-
tions of persistence, which are typically ascertained at 6
or 12 months postinitial testing.34 35
Apart from the high proportion of multiple infections
observed in our cohort, the two different sampling
methods and the 13-month gap between extended and
long-term follow-up phases might have accounted for
the long durations observed for infection clearance.
Differences in findings between the two definitions
were not unexpected; the conservative definition, by
design, provided fewer events, thus requiring a length-
ier observation period than the liberal definition.
Despite these differences, our clearance results are in
agreement with many previous studies reporting a
median duration of LR-HPV infections between 6 and
10 months.2 18 29 36 37 Typically, average durations have
been calculated in previous studies based on combining
prevalent and incident cases.15–23 These differences in
study design could affect the estimates of infection
duration. We also acknowledge the complexity surround-
ing the definition of an incident HPV infection
episode.38 Our definition was based on the extent that
we could ascertain at the outset of the study that partici-
pants were not exposed to HPV of specific types.
In our cohort, 62% of women younger than 21 years
were reported to have multiple sexual partners. Further,
women with multiple partners had a greater risk (nearly
twice) of acquiring new HR-HPV infections compared to
women with one or no sexual partners. However, the
rates were not strikingly different, as on an average,
women had 2.3 partners, reflecting the fact that only
women with <6 partners were eligible for enrolment.
Also as expected, despite the restricted age range in this
cohort, there was a clear difference in cumulative HPV
detection based on age (higher in those <21 compared
to ≥21 years), reflecting a high HPV exposure following
the onset of sexual activity.
In summary, we have observed high rates of HPV inci-
dence, which varied according to HPV risk grouping, as
well as to the type of the sample, sampling interval, age
group and number of reported sexual partners. The
primary strengths of our study were different sampling
methods, younger population from multiple centres and
comprehensive information on risk factors. Our findings
on type-specific infection according to age and other risk
factors provide insights into the natural history of HPV
infection and improve our understanding of the dynam-
ics of how infections with single and multiple HPV types
are identified on repeated sampling over time. Although
an apparent limitation, the age restriction imposed by the
design of the trial allowed us to measure the variability in
duration among HPV types at a time in a woman’s life
when her cervix is vulnerable to the oncogenic effects of
HPV infection. These observations are important in
designing strategies for infection monitoring during post-
vaccination surveillance. Our findings may also assist in
designing cervical cancer screening algorithms based on
molecular testing for HR-HPVs.
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